Chronic antithrombotic therapy in post-myocardial infarction patients.

[1]  M. Ezekowitz,et al.  Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). , 2007, The American journal of cardiology.

[2]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[3]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[4]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[5]  E. Devine,et al.  Frequency and Causes of Overanticoagulation and Underanticoagulation in Patients Treated with Warfarin , 2004, Pharmacotherapy.

[6]  G. Guyatt,et al.  Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[7]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[8]  E. Devine,et al.  Effect of Age on International Normalized Ratio at the Time of Major Bleeding in Patients Treated with Warfarin , 2004, Pharmacotherapy.

[9]  B. Gleason,et al.  Aspirin and Warfarin versus Aspirin Monotherapy after Myocardial Infarction , 2003, The Annals of pharmacotherapy.

[10]  W. Weaver,et al.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.

[11]  Ulf Bredberg,et al.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects , 2003, European Journal of Clinical Pharmacology.

[12]  U. Bredberg,et al.  Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[13]  L. Johansson,et al.  Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.

[14]  U. Eriksson,et al.  No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran , 2003, Clinical pharmacokinetics.

[15]  L. Johansson,et al.  No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers , 2003, Clinical pharmacokinetics.

[16]  D. Grobbee,et al.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2) study: a randomized controlled trial , 2002 .

[17]  David A Fitzmaurice,et al.  ABC of antithrombotic therapy : Bleeding risks of , 2002 .

[18]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[19]  G. Uijen,et al.  Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial , 2002, Circulation.

[20]  D. Grobbee,et al.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.

[21]  M. Ezekowitz,et al.  Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP Study , 2002, Circulation.

[22]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[23]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[24]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[25]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[26]  F. Monsma,et al.  Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. , 2001, The Journal of clinical investigation.

[27]  J. Pogue,et al.  Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. , 1998, Circulation.

[28]  Coumadin Aspirin Reinfarction Study Investigators.  Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction , 1997, The Lancet.

[29]  N. Maalej,et al.  Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. , 1996, Circulation.

[30]  F. Neumann,et al.  Platelet function in acute myocardial infarction treated with direct angioplasty. , 1996, Circulation.

[31]  E. Topol,et al.  Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.

[32]  C. Patrono.  Aspirin as an antiplatelet drug. , 1994, The New England journal of medicine.

[33]  D. Faulds,et al.  Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. , 1994, Drugs.

[34]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[35]  C. Madden.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .

[36]  H. Weisman,et al.  Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents a , 1991, Annals of the New York Academy of Sciences.

[37]  The Risc Group.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease , 1990, The Lancet.

[38]  J. May,et al.  Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. , 1989, Circulation.

[39]  J. Willerson,et al.  Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. , 1988, Circulation.

[40]  L Morgenstern,et al.  Coronary angioscopy in patients with unstable angina pectoris. , 1986, The New England journal of medicine.

[41]  J. Spann,et al.  Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. , 1986, The American journal of cardiology.

[42]  D. Sackett,et al.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. , 1985, The New England journal of medicine.

[43]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.